JP2008512348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512348A5 JP2008512348A5 JP2007518228A JP2007518228A JP2008512348A5 JP 2008512348 A5 JP2008512348 A5 JP 2008512348A5 JP 2007518228 A JP2007518228 A JP 2007518228A JP 2007518228 A JP2007518228 A JP 2007518228A JP 2008512348 A5 JP2008512348 A5 JP 2008512348A5
- Authority
- JP
- Japan
- Prior art keywords
- halogen
- aryl
- lower alkyl
- optionally
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 238000009472 formulation Methods 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 206010046851 Uveitis Diseases 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 208000006673 asthma Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 201000009961 allergic asthma Diseases 0.000 claims 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 208000024693 gingival disease Diseases 0.000 claims 3
- 208000007565 gingivitis Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 208000028169 periodontal disease Diseases 0.000 claims 3
- 201000001245 periodontitis Diseases 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- -1 — (CH 2 ) n —CF 3 Chemical group 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 206010036346 Posterior capsule opacification Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010010180 Renal failure complications Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010057469 Vascular stenosis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 ***N*c1ccccc1 Chemical compound ***N*c1ccccc1 0.000 description 9
- VTZOSIRDOPNJJJ-UHFFFAOYSA-N CN(C(c(cc1Cl)ccc1Cl)=O)C1=CC=C(C[IH][N](C)(C)C2CCCCC2)CC1 Chemical compound CN(C(c(cc1Cl)ccc1Cl)=O)C1=CC=C(C[IH][N](C)(C)C2CCCCC2)CC1 VTZOSIRDOPNJJJ-UHFFFAOYSA-N 0.000 description 1
- ZFBNYWPJZDVEFB-UHFFFAOYSA-N C[N](C)(Cc(cc1)ccc1NC(C(C1)C=CC(Cl)=C1Cl)=O)C1C2CCC1C2 Chemical compound C[N](C)(Cc(cc1)ccc1NC(C(C1)C=CC(Cl)=C1Cl)=O)C1C2CCC1C2 ZFBNYWPJZDVEFB-UHFFFAOYSA-N 0.000 description 1
- KZWVIZCCHJBLFX-UHFFFAOYSA-O Cc(c(Cl)c1)ccc1C(Nc1ccc(C[N+](C)(C)C2CCCCC2)cc1)=O Chemical compound Cc(c(Cl)c1)ccc1C(Nc1ccc(C[N+](C)(C)C2CCCCC2)cc1)=O KZWVIZCCHJBLFX-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/582,929 | 2004-06-24 | ||
| US58292904P | 2004-06-25 | 2004-06-25 | |
| PCT/US2005/022034 WO2006012135A1 (en) | 2004-06-24 | 2005-06-22 | Quaternary salt ccr2 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008512348A JP2008512348A (ja) | 2008-04-24 |
| JP2008512348A5 true JP2008512348A5 (enExample) | 2008-08-07 |
| JP5137572B2 JP5137572B2 (ja) | 2013-02-06 |
Family
ID=35045442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518228A Expired - Fee Related JP5137572B2 (ja) | 2004-06-24 | 2005-06-22 | 第四級塩であるｃｃｒ２アンタゴニスト |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7799824B2 (enExample) |
| EP (1) | EP1765803B1 (enExample) |
| JP (1) | JP5137572B2 (enExample) |
| KR (1) | KR101229416B1 (enExample) |
| CN (1) | CN101010312B (enExample) |
| AR (1) | AR049652A1 (enExample) |
| AU (1) | AU2005267385B2 (enExample) |
| BR (1) | BRPI0512623A (enExample) |
| CA (1) | CA2571587C (enExample) |
| EA (1) | EA012784B1 (enExample) |
| EC (1) | ECSP067116A (enExample) |
| ES (1) | ES2573845T3 (enExample) |
| IL (1) | IL180197A0 (enExample) |
| MX (1) | MX2007000036A (enExample) |
| NI (1) | NI200600319A (enExample) |
| NO (1) | NO20070387L (enExample) |
| NZ (1) | NZ552173A (enExample) |
| TW (1) | TWI407957B (enExample) |
| UA (1) | UA85597C2 (enExample) |
| WO (1) | WO2006012135A1 (enExample) |
| ZA (1) | ZA200700677B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2573845T3 (es) | 2004-06-25 | 2016-06-10 | Janssen Pharmaceutica Nv | Antagonistas de CCR2 de sales cuaternarias |
| CA2672229A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| WO2008131481A1 (en) * | 2007-04-26 | 2008-11-06 | Fibrotech Therapeutics Pty Ltd | Treatment of mesangioproliferative diseases |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| RU2010114611A (ru) | 2007-09-14 | 2011-10-20 | Баррик Гольд Корпорейшн (CA) | Способ восстановления металлов платиновой группы с использованием восстановителей |
| US8093428B2 (en) * | 2007-10-26 | 2012-01-10 | Janssen Pharmaceutica N.V. | Synthesis of quaternary salt compounds |
| US8168829B2 (en) * | 2007-10-26 | 2012-05-01 | Janssen Pharmaceutica N.V. | Synthesis of quaternary salt compounds |
| TW200927740A (en) * | 2007-11-13 | 2009-07-01 | Bial Portela & Ca Sa | Process |
| KR100954138B1 (ko) * | 2007-12-31 | 2010-04-20 | 부산대학교 산학협력단 | 지방조직 유래 줄기세포를 함유하는 알레르기 비염 또는천식 예방 및 치료제 |
| CN101481323B (zh) * | 2008-01-11 | 2013-11-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并环庚烯类衍生物、其制备方法及医药用途 |
| ES2551557T3 (es) | 2008-12-19 | 2015-11-19 | Boehringer Ingelheim International Gmbh | Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC |
| EP2947073B1 (en) | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| PL2513093T3 (pl) | 2009-12-17 | 2015-03-31 | Centrexion Therapeutics Corp | Nowi antagoniści receptora CCR2 i ich zastosowanie |
| EP2569295B1 (en) | 2010-05-12 | 2014-11-19 | Boehringer Ingelheim International GmbH | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| EP2576532B1 (en) | 2010-06-07 | 2018-07-18 | Novomedix, LLC | Furanyl compounds and the use thereof |
| US20120004298A1 (en) * | 2010-06-30 | 2012-01-05 | Hassan Chaouk | Ophthalmic devices containing chemokine antagonists |
| JP5722892B2 (ja) * | 2010-07-15 | 2015-05-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US10451897B2 (en) | 2011-03-18 | 2019-10-22 | Johnson & Johnson Vision Care, Inc. | Components with multiple energization elements for biomedical devices |
| US9102673B2 (en) | 2011-07-12 | 2015-08-11 | Merck Sharp & Dohme Corp. | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors |
| JP5786258B2 (ja) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規かつ選択的なｃｃｒ２拮抗薬 |
| US9812730B2 (en) | 2011-08-02 | 2017-11-07 | Johnson & Johnson Vision Care, Inc. | Biocompatible wire battery |
| CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| US8857983B2 (en) | 2012-01-26 | 2014-10-14 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens assembly having an integrated antenna structure |
| CA3095012C (en) | 2012-05-01 | 2023-02-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US9793536B2 (en) | 2014-08-21 | 2017-10-17 | Johnson & Johnson Vision Care, Inc. | Pellet form cathode for use in a biocompatible battery |
| US10381687B2 (en) | 2014-08-21 | 2019-08-13 | Johnson & Johnson Vision Care, Inc. | Methods of forming biocompatible rechargable energization elements for biomedical devices |
| US9383593B2 (en) | 2014-08-21 | 2016-07-05 | Johnson & Johnson Vision Care, Inc. | Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators |
| US9715130B2 (en) | 2014-08-21 | 2017-07-25 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form separators for biocompatible energization elements for biomedical devices |
| US9599842B2 (en) | 2014-08-21 | 2017-03-21 | Johnson & Johnson Vision Care, Inc. | Device and methods for sealing and encapsulation for biocompatible energization elements |
| US9941547B2 (en) | 2014-08-21 | 2018-04-10 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes and cavity structures |
| US10627651B2 (en) | 2014-08-21 | 2020-04-21 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers |
| US10361404B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Anodes for use in biocompatible energization elements |
| US10361405B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes |
| MX383744B (es) | 2015-07-02 | 2025-03-14 | Centrexion Therapeutics Corp | Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona. |
| SG11201806829TA (en) * | 2016-02-15 | 2018-09-27 | Sanofi Sa | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators |
| US10345620B2 (en) | 2016-02-18 | 2019-07-09 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices |
| EP3541809B1 (en) | 2016-11-17 | 2025-06-25 | Sanofi | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| EP3577103A1 (en) | 2017-02-03 | 2019-12-11 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
| EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| KR20210009315A (ko) | 2018-04-11 | 2021-01-26 | 오하이오 스테이트 이노베이션 파운데이션 | 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물 |
| WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| CN111808062B (zh) * | 2020-07-28 | 2022-09-13 | 遵义医科大学 | 一种蛇床子素磺酸酯类化合物及其应用 |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0873476A (ja) * | 1994-07-04 | 1996-03-19 | Takeda Chem Ind Ltd | ホスホン酸誘導体およびそれを含んでなる医薬 |
| WO1999032468A1 (en) * | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
| WO1999032100A2 (en) * | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
| JP4416198B2 (ja) * | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| EP1104416A2 (en) | 1998-08-20 | 2001-06-06 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use as anti-hiv agents |
| JP2001058988A (ja) * | 1998-12-21 | 2001-03-06 | Takeda Chem Ind Ltd | アニリド誘導体、その製造法および用途 |
| EP1140896A1 (en) | 1998-12-21 | 2001-10-10 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
| JP2001026586A (ja) * | 1999-05-07 | 2001-01-30 | Takeda Chem Ind Ltd | 環状化合物およびその用途 |
| CA2373073A1 (en) * | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| AU1734401A (en) * | 1999-12-09 | 2001-06-18 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
| US20050154016A1 (en) * | 2002-04-19 | 2005-07-14 | Katsunori Takashima | Preventives for hiv infection |
| JP2004043432A (ja) * | 2002-04-19 | 2004-02-12 | Takeda Chem Ind Ltd | Ｈｉｖ感染予防剤 |
| JP4145230B2 (ja) * | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| ES2573845T3 (es) | 2004-06-25 | 2016-06-10 | Janssen Pharmaceutica Nv | Antagonistas de CCR2 de sales cuaternarias |
| KR20070024646A (ko) * | 2004-06-25 | 2007-03-02 | 바스프 악티엔게젤샤프트 | 트리아졸로피리미딘 화합물 및 그의 병원성 진균류 방제를위한 용도 |
-
2005
- 2005-06-22 ES ES05766641.4T patent/ES2573845T3/es not_active Expired - Lifetime
- 2005-06-22 UA UAA200614021A patent/UA85597C2/ru unknown
- 2005-06-22 AU AU2005267385A patent/AU2005267385B2/en not_active Ceased
- 2005-06-22 EP EP05766641.4A patent/EP1765803B1/en not_active Expired - Lifetime
- 2005-06-22 KR KR1020077001484A patent/KR101229416B1/ko not_active Expired - Fee Related
- 2005-06-22 CN CN2005800286402A patent/CN101010312B/zh not_active Expired - Fee Related
- 2005-06-22 US US11/159,018 patent/US7799824B2/en active Active
- 2005-06-22 BR BRPI0512623-1A patent/BRPI0512623A/pt not_active Application Discontinuation
- 2005-06-22 MX MX2007000036A patent/MX2007000036A/es unknown
- 2005-06-22 CA CA2571587A patent/CA2571587C/en not_active Expired - Fee Related
- 2005-06-22 JP JP2007518228A patent/JP5137572B2/ja not_active Expired - Fee Related
- 2005-06-22 EA EA200700116A patent/EA012784B1/ru not_active IP Right Cessation
- 2005-06-22 WO PCT/US2005/022034 patent/WO2006012135A1/en not_active Ceased
- 2005-06-22 NZ NZ552173A patent/NZ552173A/en not_active IP Right Cessation
- 2005-06-24 AR ARP050102614A patent/AR049652A1/es not_active Application Discontinuation
- 2005-06-24 TW TW094121070A patent/TWI407957B/zh not_active IP Right Cessation
-
2006
- 2006-12-19 IL IL180197A patent/IL180197A0/en unknown
- 2006-12-21 NI NI200600319A patent/NI200600319A/es unknown
- 2006-12-26 EC EC2006007116A patent/ECSP067116A/es unknown
-
2007
- 2007-01-22 NO NO20070387A patent/NO20070387L/no not_active Application Discontinuation
- 2007-01-24 ZA ZA200700677A patent/ZA200700677B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11040035B2 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| KR101937501B1 (ko) | 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염 | |
| KR102932904B1 (ko) | 새로운 화합물 및 그 용도 | |
| KR102544847B1 (ko) | 4Ｈ-피롤로［3,2-ｃ］피리딘-4-온 유도체 | |
| JP2007505933A5 (enExample) | ||
| JP6804516B2 (ja) | 変異イソクエン酸デヒドロゲナーゼｉｄｈ１ ｒ１３２ｈの阻害剤 | |
| IL166855A (en) | Annals of compressed pyrimidine with azaleas that inhibit pi3k activity and drugs containing them. | |
| CN103003269B (zh) | 取代的杂环基苄基吡唑及其用途 | |
| EP2585066A2 (en) | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | |
| JP2010529193A5 (enExample) | ||
| ES2437346T3 (es) | Procedimiento para la producción de derivado de diamina | |
| CN107921286A (zh) | 1h‑吡咯‑3‑胺类化合物 | |
| JP2004517099A5 (enExample) | ||
| JP2004532235A (ja) | 望ましくないサイトカイン活性に関連する疾患を治療するのに有用なトリアゾール化合物 | |
| JP2009526831A5 (enExample) | ||
| WO2006125180B1 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| JP7338711B2 (ja) | Ｄｐアンタゴニスト | |
| JP2005508969A5 (enExample) | ||
| JP5315336B2 (ja) | 精神疾患治療用の新規化合物とその調剤及び使用 | |
| JP2010514733A5 (enExample) | ||
| JP4272056B2 (ja) | アリールピペラジンに連結したテトラヒドロインドロン及びプリン誘導体 | |
| WO1997000258A1 (en) | Tricyclic benzazepine compounds | |
| CN1111407C (zh) | 抗癌组合物 | |
| JP5960695B2 (ja) | パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用 | |
| WO2012130850A1 (de) | Gewebetargeting mit onkoziden verbrückten diphenylderivaten zur selektiven behandlung von sexualorgantumoren |